microRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1

Chinese Journal of Cancer Research

Volumn 27, Issue 3, 2015, Pages 247-257

  Liu, Zhe ^a   Xu, Yuanhong ^a   Long, Jin ^a   Guo, Kejian ^a   Ge, Chunlin ^a   Du, Ruixia ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; High mobility group box 1 (HMGB1); MicroRNA 218 (miR 218); Pancreatic cancer; Proliferation

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; MICRORNA; MICRORNA 218; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER TISSUE; CELL COUNTING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; WESTERN BLOTTING;

EID: 84940181647     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.3978/j.issn.1000-9604.2015.04.07     Document Type: Article

References (57)

1. Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res 2014;26:48-58.
2. Rossi RE, Massironi S, Conte D, et al. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014;2:8.
3. Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol 2014;5:280-95.
4. Rozengurt E. Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol 2014;5:357.
5. Liu J, Song R, Cui M. Numerical simulation on hydromechanical coupling in porous media adopting three-dimensional pore-scale model. ScientificWorldJournal 2014;2014:140206.
6. Moir J, White SA, French JJ, et al. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Eur J Surg Oncol 2014;40:1598-604.
7. Burkey MD, Feirman S, Wang H, et al. The association between smokeless tobacco use and pancreatic adenocarcinoma: a systematic review. Cancer Epidemiol 2014;38:647-53.
8. Ito M, Makino N, Ueno Y. Glucose intolerance and the risk of pancreatic cancer. Transl Gastrointest Cancer 2013;2:223-29.
9. Furuse J, Nagashima F. Current status and future direction of chemotherapy for pancreatic cancer. Chin Clin Oncol 2013;2:6.
10. Xu K, Niu L, Yang D. Cryosurgery for pancreatic cancer. Gland Surg 2013;2:30-9.
11. Garajová I, Le Large TY, Frampton AE, et al. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int 2014;2014:678401.
12. Valle JW, Faivre S, Hubner RA, et al. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 2014;40:1230-8.
13. Chitkara D, Mittal A, Mahato RI. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. Adv Drug Deliv Rev 2015;81:34-52.
14. Pulito C, Donzelli S, Muti P, et al. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med 2014;2:58.
15. Chen BJ, Wu YL, Tanaka Y, et al. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci 2014;10:1084-96.
16. Kelly RS, Vineis P. Biomarkers of susceptibility to chemical carcinogens: the example of non-Hodgkin lymphomas. Br Med Bull 2014;111:89-100.
17. Hu Y, Tang H. MicroRNAs regulate the epithelial to mesenchymal transition (EMT) in cancer progression. Microrna 2014;3:108-17.
18. Zaccagna F, Anzidei M, Sandolo F, et al. MRgFUS for liver and pancreas cancer treatments: the Umberto I hospital experience. Transl Cancer Res 2014;3:430-41.
19. Wang Q, Wei L, Guan X, et al. Briefing in family characteristics of microRNAs and their applications in cancer research. Biochim Biophys Acta 2014;1844:191-7.
20. Kaplan BB, Kar AN, Gioio AE, et al. MicroRNAs in the axon and presynaptic nerve terminal. Front Cell Neurosci 2013;7:126.
21. Li M, Fu W, Wo L, et al. miR-128 and its target genes in tumorigenesis and metastasis. Exp Cell Res 2013;319:3059-64.
22. Leite-Moreira AM, Lourenço AP, Falcão-Pires I, et al. Pivotal role of microRNAs in cardiac physiology and heart failure. Drug Discov Today 2013;18:1243-9.
23. Piva R, Spandidos DA, Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 2013;43:985-94.
24. Palumbo S, Miracco C, Pirtoli L, et al. Emerging roles of microRNA in modulating cell-death processes in malignant glioma. J Cell Physiol 2014;229:277-86.
25. Ghosh A, Berger A. Opioids, adjuvants, and interventional options for pain management of symptomatic metastases. Ann Palliat Med 2014;3:172-91.
26. Francis T, Graf A, Hodges K, et al. Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg Nutr 2013;2:216-26.
27. Wang J, Paris PL, Chen J, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 2015;356:404-9.
28. Wang J, Raimondo M, Guha S, et al. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer 2014;5:696-705.
29. Huang X, Lv W, Zhang JH, et al. miR‑96 functions as a tumor suppressor gene by targeting NUAK1 in pancreatic cancer. Int J Mol Med 2014;34:1599-605.
30. Tu Y, Gao X, Li G, et al. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 2013;73:6046-55.
31. Jin J, Cai L, Liu ZM, et al. miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev 2013;14:3681-4.
32. Zhu Z, Xu Y, Du J, et al. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival. J Surg Oncol 2014;109:89-94.
33. Zarogoulidis P, Pavlioglou P, Pivert PL, et al. Current and future intratumoral targeted treatment for pancreatic cancer. Ther Deliv 2014;5:913-26.
34. Li X, Truty MA, Kang Y, et al. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin Cancer Res 2014;20:6529-40.
35. Tholey RM, Lal S, Jimbo M, et al. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Mol Cancer Res 2015;13:439-48.
36. Nakata D. Increased N-glycosylation of Asn88 in serum pancreatic ribonuclease 1 is a novel diagnostic marker for pancreatic cancer. Sci Rep 2014;4:6715.
37. Schönhuber N, Seidler B, Schuck K, et al. A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. Nat Med 2014;20:1340-7.
38. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014;159:80-93.
39. Zhang J, Ma L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Rev 2012;31:653-62.
40. Izzotti A, Cartiglia C, Steele VE, et al. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res 2012;751:287-303.
41. Vira D, Basak SK, Veena MS, et al. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev 2012;31:733-51.
42. Link A, Kupcinskas J, Wex T, et al. Macro-role of microRNA in gastric cancer. Dig Dis 2012;30:255-67.
43. Karsy M, Arslan E, Moy F. Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme. Genes Cancer 2012;3:3-15.
44. Shi J, Yang L, Wang T, et al. miR-218 is downregulated and directly targets SH3GL1 in childhood medulloblastoma. Mol Med Rep 2013;8:1111-7.
45. Guan H, Wei G, Wu J, et al. Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab 2013;98:E1334-44.
46. Palmblad K, Schierbeck H, Sundberg E, et al. High Systemic Levels of the Cytokine-Inducing HMGB1 Isoform Secreted in Severe Macrophage Activation Syndrome. Mol Med 2015;20:538-47.
47. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Aspects Med 2014;40:1-116.
48. Srinivasan M, Banerjee S, Palmer A, et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer 2014;5:127-39.
49. Zhou TB. Role of high mobility group box 1 and its signaling pathways in renal diseases. J Recept Signal Transduct Res 2014;34:348-50.
50. Chen R, Hou W, Zhang Q, et al. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 2013;19:357-66.
51. Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol Ther 2014;141:347-57.
52. Abe A, Kuwata T, Yamauchi C, et al. High Mobility Group Box1 (HMGB1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts. Pathol Int 2014;64:267-75.
53. Ueda M, Takahashi Y, Shinden Y, et al. Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res 2014;34:5357-62.
54. Parker KH, Sinha P, Horn LA, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 2014;74:5723-33.
55. Zuo Z, Che X, Wang Y, et al. High mobility group Box-1 inhibits cancer cell motility and metastasis by suppressing activation of transcription factor CREB and nWASP expression. Oncotarget 2014;5:7458-70.
56. Meng Q, Zhao J, Liu H, et al. HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma. Tumour Biol 2014;35:12265-74.
57. Wang W, Zhu H, Zhang H, et al. Targeting HMGB1 inhibits bladder cancer cells bioactivity by lentivirus-mediated RNA interference. Neoplasma 2014;61:638-46.